Trump’s Shocking $100 Billion Venezuela Oil Push: How U.S. Protection Could Rewrite Global Energy Power
In a dramatic shift in U.S. foreign and economic policy, President Donald Trump has called on major American oil companies
OpenAI Unveils ChatGPT Health in the US, Promising Smarter Medical Insights but Raising Privacy Fears
OpenAI has introduced a new feature called ChatGPT Health in the United States, marking a major step toward personalized artificial
U.S. Considers Paying Greenlanders to Sway Support as Trump Pushes Arctic Ambitions
President Donald Trump’s long-running fascination with Greenland is back in the spotlight. Once again, Trump has openly expressed interest in
MiniMax’s Explosive Hong Kong Debut Signals China’s AI IPO Wave Is Just Getting Started
China’s artificial intelligence race just got a fresh jolt of excitement. MiniMax, a fast-rising Chinese AI company, made a powerful
Nvidia CEO Jensen Huang Shrugs Off Potential $8 Billion Billionaire Tax
Nvidia Chief Executive Officer Jensen Huang says he would be “perfectly fine” paying an estimated $7.75 billion in taxes if
Trump Withdraws U.S. From Dozens of International Organizations, White House Says
U.S. President Donald Trump has signed a proclamation withdrawing the United States from dozens of international organizations, according to a
China’s First “AI Tiger” Goes Public as Zhipu Debuts in Hong Kong
China’s artificial intelligence sector reached a major milestone this week as Zhipu, one of the country’s leading large language model
Samsung Expects Record Profit as AI Drives Memory Chip Demand
Samsung Electronics is set to deliver one of the strongest financial performances in its history, fueled by a sharp rise
What Comes After a Decade of U.S.-China Competition? AmCham China Chair Sees a Possible Reset
After nearly three decades of navigating the shifting terrain of U.S.-China relations, James Zimmerman has learned to temper optimism with
Big Pharma Races to Snap Up Biotech Assets as $170 Billion Patent Cliff Nears
Global pharmaceutical giants are accelerating efforts to acquire biotech companies and late-stage drug assets as the industry braces for a